MAP2K7 and breast carcinoma: Given that the RAF-MAP2K/MEK-MAPK1/3 signaling pathway is frequently activated in breast cancer, particularly in TNBC, the common downregulation of ULK1 in breast cancer supports the rationale for using MAP2K/MEK-MAPK1/3 pathway inhibitors to treat breast cancer bone metastasis (70).